A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia.

Trial Profile

A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs BI 836826 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 17 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 22 Jun 2017 Planned End Date changed from 1 Jan 2017 to 11 Jul 2017.
    • 22 Jun 2017 Planned primary completion date changed from 1 Jan 2017 to 23 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top